Dynavax expects to receive nearly $200m in milestone payments over the term of the alliance.
Dynavax and GSK will focus on the development of a TLR8 inhibitor to treat multiple autoimmune and inflammatory diseases.
TLR inhibitors are oligonucleotides, called immunoregulatory sequences (IRS), which cause the inhibition of TLR-induced inflammatory response linked to autoimmune and inflammatory diseases.